Physician profile
George Manja
NPI 1346242773
$12,209.51
in general payments reported to CMS, 2019-2025
31 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $922 · 2021: $1,844 · 2022: $1,418 · 2023: $1,805 · 2024: $2,153 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,536 · Education: $48.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,535.91 |
| Education | $48.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,368.51 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,444.49 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,746.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,390.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $432.58 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $314.53 | 2021-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $267.64 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $251.57 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $225.79 | 2019-2022 | |
| Allergan, INC. | $223.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.16 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $176.16 | 2024-2025 | Voquezna |
| Amgen INC. | $168.61 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $124.74 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $124.00 | 2024 | Xarelto |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $99.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $94.38 | 2019-2024 | Zoryve |
| Abbott Laboratories | $80.65 | 2021-2022 | |
| Exact Sciences Corporation | $73.82 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $71.85 | 2021 | |
| Amarin Pharma, INC. | $49.44 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.93 | 2022 | |
| Nabriva Therapeutics, Plc | $34.58 | 2020 | |
| Medline Industries LP | $33.48 | 2019 | |
| Genentech USA, INC. | $32.64 | 2020-2021 | |
| Melinta Therapeutics, LLC | $27.73 | 2019 | |
| Biogen, INC. | $19.50 | 2020 | |
| Eisai INC. | $16.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.06 | 2019 | |
| Axsome Therapeutics, INC. | $15.48 | 2023 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Manja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.